Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines

Kanno,Syu-Ichi; Itoh,Katsuyuki; Suzuki,Naoto; Tomizawa,Ayako; Yomogida,Shin; Ishikawa,Masaaki

doi:10.3892/mco.2012.3

Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines

Authors:
- Syu-Ichi Kanno
- Katsuyuki Itoh
- Naoto Suzuki
- Ayako Tomizawa
- Shin Yomogida
- Masaaki Ishikawa
View Affiliations

Affiliations: Department of Clinical Pharmacotherapeutics, Tohoku Pharmaceutical University, Aoba-ku, Sendai 981-8558, Japan
Published online on: June 27, 2012 https://doi.org/10.3892/mco.2012.3
Pages: 29-34

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sorafenib is an orally administered multikinase inhibitor that exhibits anti-angiogenic and anti-tumor activity. Sorafenib is also known to bind to protein (>99.5%), suggesting protein binding may be involved in sorafenib pharmacokinetic variability. Albumin is a major drug-binding protein. In this study, we examined the effect of albumin on sorafenib-induced cytotoxicity using two in vitro culture cell lines, human hepatoma Huh-7 cells and androgen-independent prostate cancer PC-3 cells. The cells were cultured and incubated, and cytotoxicity was assessed. Results were confirmed by western blotting. The presence of exogenous albumin markedly blocked the sorafenib-induced cytotoxicity in the two cell lines. Albumin concentration, the change of pharmacological signal transduction as Raf-B, vascular endothelial growth factor (VEGF), and phosphorylation of MEK1/2 or ERK1/2 were found to be decreased by sorafenib. Co-incubation of warfarin, a representative coumarin anticoagulant and potent binding activity, with albumin enhanced the cytotoxic effects by sorafenib. These mechanisms depend on the high binding properties of sorafenib and exogenous albumin. Furthermore, we investigated the effects of endogenous albumin expression on sorafenib-induced cytotoxicity using the siRNA knockdown system or transfected expression vector assay. However, the cytotoxic effects by sorafenib showed little change either with the knockdown or overexpression of albumin. Our results suggest that particular care should be taken with albuminemia or the combined use of drugs with a high affinity for albumin, such as warfarin, and sorafenib in the treatment of cancer patients. Our findings may be useful to the cancer therapeutic strategy by sorafenib.

View Figures

View References

1.	Peters T: All About Albumin: Biochemistry, Genetics, and Medical Applications. Academic Press; San Diego: 1996
2.	Ballmer PE, McNurlan MA, Milne E, Heys SD, Buchan V, Calder AG and Garlick PJ: Measurement of albumin synthesis in humans: a new approach employing stable isotopes. Am J Physiol. 259:E797–E803. 1990.
3.	Waldmann TA: Protein-losing enteropathy and kinetic studies of plasma protein metabolism. Semin Nucl Med. 2:251–263. 1972.
4.	Ballmer PE, Walshe D, McNurlan MA, Watson H, Brunt PW and Garlick PJ: Albumin synthesis rates in cirrhosis: correlation with Child-Turcotte classification. Hepatology. 18:292–297. 1993.
5.	Pasanisi F, Orban A, Scalfi L, Alfonsi L, Santarpia L, Zurlo E, Celona A, Potenza A and Contaldo F: Predictors of survival in terminal-cancer patients with irreversible bowel obstruction receiving home parenteral nutrition. Nutrition. 17:581–584. 2001.
6.	Ruot B, Breuillé D, Rambourdin F, Bayle G, Capitan P and Obled C: Synthesis rate of plasma albumin is a good indicator of liver albumin synthesis in sepsis. Am J Physiol Endocrinol Metab. 279:E244–E251. 2000.
7.	Ballmer PE: Causes and mechanisms of hypoalbuminaemia. Clin Nutr. 20:271–273. 2001.
8.	Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 5:835–844. 2006.
9.	Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
10.	Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66:11851–11858. 2006.
11.	Escudier B, Eisen T, Stadler WM, et al: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 27:3312–3318. 2009.
12.	Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
13.	Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140. 2008.
14.	Kloos RT, Ringel MD, Knopp MV, et al: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 27:1675–1684. 2009.
15.	Dahut WL, Scripture C, Posadas E, et al: A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res. 14:209–214. 2008.
16.	Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J and Figg WD: Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol. 72:294–305. 2011.
17.	Tod M, Mir O, Bancelin N, et al: Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res. 28:3199–3207. 2011.
18.	Villarroel MC, Pratz KW, Xu L, Wright JJ, Smith BD and Rudek MA: Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. Invest New Drugs. Nov 17–2011, (E-pub ahead of print).
19.	Kanno S, Kurauchi K, Tomizawa A, Yomogida S and Ishikawa M: Albumin modulates docosahexaenoic acid-induced cytotoxicity in human hepatocellular carcinoma cell lines. Toxicol Lett. 200:154–161. 2011.
20.	Kanno S, Higurashi A, Watanabe Y, Shouji A, Asou K and Ishikawa M: Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell lines. Toxicol Lett. 152:149–158. 2004.
21.	Kanno SI, Maeda N, Tomizawa A, Yomogida S, Katoh T and Ishikawa M: Involvement of p21^waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells. Int J Oncol. 40:1391–1396. 2012.
22.	Tesseromatis C and Alevizou A: The role of the protein-binding on the mode of drug action as well the interactions with other drugs. Eur J Drug Metab Pharmacokinet. 33:225–230. 2008.
23.	Mather JP: Making informed choices: medium, serum, and serum-free medium. How to choose the appropriate medium and culture system for the model you wish to create. Methods Cell Biol. 57:19–30. 1998.
24.	Fanali G, di Masi A, Trezza V, Marino M, Fasano M and Ascenzi P: Human serum albumin: from bench to bedside. Mol Aspects Med. 33:209–290. 2012.
25.	Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, Coriat R, Francès C, Knebelmann B and Goldwasser F: Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf. 9:275–287. 2010.
26.	Ullén A, Farnebo M, Thyrell L, Mahmoudi S, Kharaziha P, Lennartsson L, Grandér D, Panaretakis T and Nilsson S: Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int J Oncol. 37:15–20. 2010.
27.	Sun S, Wang M, Su L, Li J, Li H and Gu D: Study on warfarin plasma concentration and its correlation with international normalized ratio. J Pharm Biomed Anal. 42:218–222. 2006.